Clinical trials: Magnesium Level
Pulmonary Disease, Chronic Obstructive
Safety, Blood Levels and Effects of GW642444
GW642444 (the study medicine) is a new experimental medicine for treating asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00469040
- Testing
- GW642444M for 14 days
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Infections, HIV Infections
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study
To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate.
- Conditions
- Cytomegalovirus Infections, HIV Infections, Hypocalcemia
- Trial name
- NCT00002146
- Testing
- Magnesium sulfate, Foscarnet sodium
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Astra USA
Bronchiolitis, Magnesium, Abnormal Blood Level
Efficacy of Magnesium Sulfate in the Treatment of Bronchiolitis
In this study, investigators will compare the efficacy and safety of intravenous (IV) Magnesium sulfate in decreasing bronchiolitis clinical severity score and the duration of hospitalization in admitted patients, as compared to…
- Trial name
- NCT02145520
- Testing
- Magnesium Sulfate
- Where
- Qatar
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Magnesium Deficiency
Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels
This is a double-blind, placebo-controlled parallel trial designed to evaluate the effectiveness of Qualia Magnesium+® supplementation on red blood cell (RBC) magnesium levels in adults aged 21 and older.
- Trial name
- NCT06979648
- Testing
- Qualia Magnesium+®
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Qualia Life Sciences
Primary Biliary Cholangitis
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy
- Trial name
- EPICS-IV (NCT07424677)
- Testing
- Saroglitazar Magnesium 1 mg
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Zydus Therapeutics Inc.